Injectable Solution Choices between oral tirzepatide and injectable options can be confusing
Semaglutide (Ozempic, Wegovy): GLP-1 receptor agonist 31-amino acid peptide Position 2: Aib substitution Position 20: Lys acylated with a C18 fatty diacid via a Glu-(AEEA-AEEA) linker Position 28: Arg substitution Tirzepatide (Mounjaro, Zepbound): Dual GIP/GLP-1 receptor agonist 39-amino acid peptide: Position 2 and 13: Aib substitution Position 20: Lys acylated with a C20 fatty diacid via a Glu-(AEEA-AEEA) linker Position 30-39: Amino acid sequence from exenatide Retatrutide: Triple GLP-1/GIP/GCG receptor agonist 39-amino acid peptide: Position 2 and 20: Aib substitution Position 13: Leucine modified with an -methyl group (2-Methylleucine) Position 17: Lys acylated with a C20 fatty diacid via a Glu-(AEEA) linker Position 30-39: Amino acid sequence from exenatide Semaglutide and Tirzepatide are widely available and well-studied, while Retatrutide's long-term effectiveness and safety profile are still being investigated in clinical trials
The altered levels of Trp may be owing to the UA-induced dysfunction of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP) [36]
GLP-1 = GLP-1 glucagon-like peptide-1
Combined with the way it totally flattened out post-meal glucose levels, exendin-4 seemed to him like a blunter tool than what drugmakers should ultimately be shooting for
The fundamental difference is that GLP-1 agonists eliminate hunger and create a state of pharmaceutical appetite suppression, while AOD-9604 leaves appetite entirely unchanged
